George Vlachogiannis: Radical surgery vs RTH for sacral chordoma treatment
George Vlachogiannis, Executive Editor of Cancer Control at Sage Publishing, shared an article by Aneta Maria Borkowska, et al. on LinkedIn:
“A retrospective study on long-term outcomes of sacral chordoma from the Maria Sklodowska – Curie National Research Institute of Oncology confirms that radical surgery remains the gold standard for treatment, offering significantly better overall survival (OS) compared to radiotherapy (RTH). However, for inoperable cases, high-dose RTH remains an effective alternative.
Key findings:
- Patients undergoing radical surgery had superior OS (median 68 months vs. 62.3 months for RTH, p=0.01).
- No significant difference in disease-free survival (DFS) between surgical and RTH groups.
- Recurrence remains a challenge – neither surgery nor RTH showed clear survival benefits in treating recurrent cases.
- Advanced radiotherapy techniques (proton/carbon ion therapy) could improve future outcomes.
Findings reinforce the critical role of surgery in achieving the best survival outcomes while highlighting the need for improved strategies for recurrence management. They also emphasize the need for further research comparing modern radiotherapy vs. surgical approaches for this rare and aggressive cancer.”
Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study.
Authors: Aneta Maria Borkowska, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023